Targeting CDK 4/6. Jee Hyun Kim, M.D., Ph.D. Seoul National University College of Medicine
|
|
- Linette Golden
- 6 years ago
- Views:
Transcription
1 GBCC Education Symposium Targeting CDK 4/6 Jee Hyun Kim, M.D., Ph.D. Seoul National University College of Medicine
2 Contents Cyclins -CDKs in cell cycle control CDK 4/6 in breast cancer Preclinical development of CDK inhibitors Clinical development of CDK inhibitors and ongoing trials Future implications
3 Cell cycle & cyclin dependent kinases Cell cycle : tightly regulated in normal conditions with well defined phases Cyclin Dependent Kinases: Family of serine/threonine protein kinases, that are activated on interaction with their partner cyclins CDK1-4, 6 : regulate transition through specific checkpoints in the cell cycle CDK4 & 6 cyclin D, CDK2 cyclin E then A CDK7-9 : involved in regulation of the transcriptional machinery CDK5 : involved in neuron-specific functions
4 Cell cycle regulation by Cyclin CDK INK4 family Negative regulators of CDK4/6 signalling INK 4 family: p15, 16, 18, 19 CIP/KIP (p21, p27, p57) CDK4/6 & Cyclin D have a crucial role in regulation of G1/S transition
5 Cell cycle dysregulation Dysregulated cell division resulting in uncontrolled cellular proliferation : one of the key hallmarks of cancer Rb Loss/mutation Cyclin D1 amplification Altered expression of cyclins Altered expression or mutation in CDKs Loss of CDK suppressor function CDK inhibition has long been ideal targets for drug development
6 O Leary B, et al. Nature Rev Clin Oncol 2016 Finn RS, et al. Breast Cancer Res 2016 Cyclin D CDK 4/6 alterations in breast cancer In luminal ER positive breast cancer, ER signaling activates the CCND1 promoter Cyclin D1 binds to ER and facilitates ER transcriptional activity Cyclin D1 is expressed at a high level, with or without CCND1 gene amplification in many ER positive breast cancers Amplification of CDK4 and cyclin D1 reported in 15-25% breast cancer Cyclin D1 overexpression occur in over half of all breast cancers Amplification of both cyclin D1 and CDK4 is especially high in luminal B (58% and 25%) and HER2 positive subtypes (29% and 14%) Endocrine resistance is associated with persistent cyclin D1 expression and RB phosphorylation.
7 First generation CDK inhibitors Pan-CDK inhibitors, not specific for single CDK enzyme Flavopiridol Minimal single agent activity Severe toxicities: infusion site irritation, GI toxicity, severe neutropenia Unacceptable rate of neutropenia in MBC, probably d/t inhibition of transcription by the compounds effects on CDK9 and possibly 7 UCN-01 Stausporine analog, G1/S phase cell cycle arrest Severe DLTs : hyperglycemia, arrhythmia, pulmonary dysfunction
8 PD (palbociclib) inhibits proliferation of luminal ER-positive human breast cancer cell lines in vitro Clin Cancer Res 2014, Finn RS Breast Cancer Res 2009
9 Effects of palbociclib on phosphorylation of Rb gene product Finn RS Breast Cancer Res 2009
10 Palbociclib induces cell cycle arrest in sensitive cell lines but not in resistant control Sensitive treated G0/G1 S G2 Resistant Finn RS Breast Cancer Res 2009
11 % inhibition Trastuz umab Palbociclib + Trastuzumab Palbociclib Palbociclib + Tamoxifen Tamoxifen Palbociclib
12 Combination of palbociclib and anti -estrogens Phase 1 Clinical study to test safety and efficacy of CDK4/6 inhibition by palbociclib in combination with anti-estrogen drugs in ER positive breast ca Dose : oral palbociclib 125mg once daily Schedule : 3 weeks on followed by 1 week off treatment in a 28-day cycle No drug-drug interactions Most common adverse events : neutropenia, leucopenia, and fatigue
13 PALOMA-1: Phase 2 Design Finn RS Lancet Oncol 2014
14 PALOMA-1 Study Statistical Analyses Primary Endpoint Progression-free survival (PFS) Designed to detect 50% improvement in median PFS from 9 to 13.5 months (80% power, 1-sided = 10%) : 150 patients Interim Analysis 1 (Part 1) Statistically significant improvement in PFS(HR = 0.35;P =0.006) Exploratory biomarkers for CCND1 gains or p16 loss did not add to ER+ alone as a selection marker Interim Analysis 2 (combined Part 1 + Part 2) ~50% of total events (57 PFS events), data cutoff July 2012 Final Analysis (combined Part 1 + Part 2) 114 PFS events needed
15 Baseline Characteristics Palbociclib + Letrozole (n=84) Letrozole (n=81) Median Age, years(range) 62(41-89) 64(38-84) ECOG PS, n(%) 0 46(55) 45(56) 1 38(45) 36(44) Disease Site Visceral 37(44) 43(53) Bone only 18(21) 12(15) Other (Non-Visceral) 29(34) 26(32) Disease-Free Interval, n(%) >12 months from adjuvant to recurrence 34(29) 30(37) 12 months form adjuvant to recurrence 60(71) 51(63) Prior Systemic Treatment, n(%) None 44(52) 37(36) Chemotherapy 34(40) 37(46) Hormonal 26(31) 28(35)
16 Progression free Survival HR (95% CI: ) P= Median PFS: 10.2 vs 20.2 months Finn RS Lancet Oncol 2014
17 Overall survival Finn RS Lancet Oncol 2014
18 Treatment-Related Adverse Events
19 PALOMA-2 Study design ER+, HER2- BC Locoregionally recurrent or metastatic disease No prior systemic therapy R A N D O M I Z A T I O N 2:1 Palbociclib + Letorozole Placebo + Letrozole N=650 Postmenopausal women only Primary endpoint: PFS
20 Palbociclib + Fulvestrant (n=347) Placebo + Fulvestrant (n=174) Median Age, years(range) ECOG PS, n(%) 0 207(59.7) 115(66.1) 1 140(40.3) 48(33.9) HR status ER positive and PR positive 238 (68.6) 111 (63.8) ER positive and PR negative 91 (26.2) 48 (27.6) Menopausal status at entry Premenopausal or perimenopausal 72 (20.7) 36 (20.7) Postmenopausal 275 (79.3) 138 (79.3) Visceral metastases, n(%) 206 (59.4) 105 (60.3) Disease-Free Interval, n(%) 24 months 42/235 (17.9) 23/124 (18.5) >24 months 186/235 (79,1) 95/124(76.6) Prior Systemic Treatment, n(%) None 44(52) 37(36) Chemotherapy 34(40) 37(46) Hormonal 26(31) 28(35)
21 RESULTS : Efficacy of Palbociclib in Combination with Fulvestrant Turner NC, et al. NEJM 2015
22 RESULTS : Efficacy of Palbociclib in Combination with Fulvestrant
23
24 RESULTS : Adverse Events Turner NC, et al. NEJM 2015
25 RESULTS : Adverse Events Turner NC, et al. NEJM 2015
26 Neutropenia associated with CDK inhibitors Differs from that seen with cytotoxic chemotherapy Transient, reversible, does not lead to febrile neutropenia Hu W, et al. CCR 2016
27 Anti-proliferative, apoptotic, DNA damage response, and cellular senescence effects of palbociclib, doxorubicin, and paclitaxel Hu W, et al. CCR 2016
28 CDK inhibitors Palbociclib Abemaciclib Ribociclib T1/ hr 17-38h 24-36hr Dosing CDK in vitro inhibition profile (IC50) 125mg po qd D1-21, q 4 weeks CDK1 10µM CDK2 10µM CDK4 (cyclin D1):11nM CDK4 (cyclin D3): 9nM CDK5 10µM CDK6 (CyclinD2):15nM 150mg po bid CDK1 1µM CDK2 500nM CDK4 (cyclin D1): 2nM CDK6: 5nM CDK7: 300nM CDK9: 57nM Phase Approved Ⅲ Ⅲ Major AEs Other Neutropenia Thrombocytopenia Fatigue Diarrhea Neutropenia` Crosses BBB 600mg po qd CDK1 100µM CDK2 50µM CDK4 (cyclin D1): 10nM CDK6 (Cyclin D2):40nM Neutropenia Thrombocytopenia QTc interval
29 Ongoing trials with palbociclib Trial Ph Setting Primary endpoint PALOMA-4 Ⅲ Asian MBC postmenopausal PENELOPE-B Ⅲ Adjuvant (RD after neoadjuvant chemo & surgery) Number of patients Trial status PFS 330 Recruiting Invasive DFS 1100 Recruiting PALLAS Ⅲ Adjuvant idfs 4600 Recruiting NeoPAL Ⅱ Neoadjuvant RCB Recruiting PALLET Ⅱ Neoadjuvant Ki67 change ccr 306 Recruiting PEARL Ⅲ MBC PFS 348 Recruiting Young PEARL Ⅱ MBC PFS 122 Not yet recruiting
30 Ongoing trials with abemaciclib Trial Ph Setting Primary endpoint Abemaciclib combination Number of patients Trial status Ⅰb MBC Safety 102 Completed accrual MONARCH1 Ⅱ MBC ORR 128 Completed accrual MONARCH2 (JPBL) MONARCH3 (JPBM) Ⅲ MBC PFS 630 Completed accrual Ⅲ MBC 1 st line PFS 450 Completed accrual NeoMONARCH Ⅱ Neoadjuvant Ki67 change 220 Recruiting Brain metastases Ⅱ MBC, NSCLC, Melanoma Objective intracranial RR 247 Recruiting MonarchHER Ⅱ HER2+ HR+ PFS 225 Not yet recruiting
31 Ongoing trials with ribociclib Trial Ph Setting Primary endpoint No. of patients Trial status MONALEESA-2 Ⅲ MBC, 1 st line PFS 667 Completed accrual MONALEESA-3 Ⅲ MBC PFS 660 Recruiting MONALEESA-7 Ⅲ MBC, premenopausal PFS 660 Recruiting Neoadjuvant Ⅱ Neoadjuvant PEPI score 120 Recruiting LEE011+BYL719 Ⅰ/Ⅱ MBC Safety 216 Recruiting T-DM1 + LEE011 Ⅰ/Ⅱ MBC, HER2+ MTD/CBR 86 Recruiting TRINITI-1 (everolimus + exemestane ± LEE011) Ⅰ/Ⅱ MBC after CDKi failure MTD/CBR 40 Recruiting
32 Early adaptive resistance to CDK inhibitors Resistance develop rapidly, within 72 hrs Herrera-Abreu MT, et al. Cancer Res 2016;1-13
33 Combined targeting of both CDK4/6 and PI3K can block early adaptation Herrera-Abreu MT, et al. Cancer Res 2016;1-13
34 Combined targeting of both CDK4/6 and PI3K can block early adaptation Herrera-Abreu MT, et al. Cancer Res 2016;1-13
35 Combination of CDK 4/6 PI3K inhibitors does not resensitize cancer with acquired resistance but prevents CDK 4/6 resistance Support clinical development of combinations of CDK4/6 and PI3K/mTOR inhibitors & triplet combinations (fulvestrant, CDK4/6, PI3K) in ER positive cancers. Herrera-Abreu MT, et al. Cancer Res 2016;1-13
36 Future challenges Which endocrine therapy partner in ER positive breast cancer? Aromatase inhibitor in endocrine therapy naive setting Fulvestrant in endocrine therapy pretreated breast cancer Which combination therapy? PI3K inhibitors and mtor inhibitors HER2 inhibitors
37 Summary Cyclin D- CDK 4/6 complex have pivotal role in the transition from G1 to S phase CDK inhibitors are rational targeted agent in ER positive breast cancer Cyclin D1 is expressed at a high level Endocrine resistance is associated with persistent cyclin D1 expression and RB phosphorylation in many ER positive breast cancers CDK inhibitors in combination with aromatase inhibitors or fulvestrant demonstrated significant activity in ER+ breast cancer with manageable toxicities (neutropenia without fever) CDK inhibitor clinical trials are ongoing under many different indications (neoadjuvant/adjuvant, in HER2+) and with various combinations to overcome resistance
Inibitori delle chinasi ciclino dipendenti nel trattamento della malattia metastatica HR-positiva Gli studi clinici
Inibitori delle chinasi ciclino dipendenti nel trattamento della malattia metastatica HR-positiva Gli studi clinici Laura Orlando UOC Oncologia & Breast Unit Brindisi Verona 22/04/2016 Summary Studi con
More informationMultimedia Appendix 6 Educational Materials Table of Contents. Intervention Educational Materials Audio Script (version 1)
Multimedia Appendix 6 Educational Materials Table of Contents Intervention Educational Materials... 1 Audio Script (version 1)... 1 Text (version 1)... 5 Slides (version 1)... 17 Audio Script (version
More informationMetastatic breast cancer: sequence of therapies
Metastatic breast cancer: sequence of therapies Clinical Case Discussion Nadia Harbeck, MD PhD Breast Center, Department of Gynecology and Obstetrics University of Munich, Ludwig-Maximilians University
More informationOutline of the presentation
Outline of the presentation Breast cancer subtypes and classification Clinical need in estrogen-positive (ER+) metastatic breast cancer (mbc) Sulforaphane and SFX-01: the preclinical evidence STEM Phase
More informationRecent advances in the management of metastatic breast cancer in older adults
Recent advances in the management of metastatic breast cancer in older adults Laura Biganzoli Medical Oncology Dept New Hospital of Prato Istituto Toscano Tumori Italy Important recent advances in the
More informationRIBOCICLIB EN PRIMERA LINEA DE TRATAMIENTO. Dra. Elena Aguirre H.U. Miguel Servet
RIBOCICLIB EN PRIMERA LINEA DE TRATAMIENTO Dra. Elena Aguirre H.U. Miguel Servet INTRODUCTION ADVANCED BREAST CANCER HR+/HER2- YES Consider Chemo VISCERAL CRISIS? NO Endocrine Therapy X3 Toxicity Progresive
More informationOvercoming resistance to endocrine or HER2-directed therapy
Overcoming resistance to endocrine or HER2-directed therapy Jane Lowe Meisel, MD Assistant Professor of Hematology and Medical Oncology Winship Cancer Institute at Emory University 1 Background While most
More informationMetastatic Breast Cancer What is new? Subtypes and variation?
Metastatic Breast Cancer What is new? Subtypes and variation? Anne Blaes, MD, MS University of Minnesota, Division of Hematology/Oncology Director, Adult Cancer Survivor Program Current estimates for metastatic
More informationUpdate on New Perspectives in Endocrine-Sensitive Breast Cancer. James R. Waisman, MD
Update on New Perspectives in Endocrine-Sensitive Breast Cancer James R. Waisman, MD Nothing to disclose DISCLOSURE TAILORx Oncotype Recurrence Score TAILORx Study Design Sparano, J Clin Oncol 2008;26:721-728
More informationWhat is new in HR+ Breast Cancer? Olivia Pagani Breast Unit and Institute of oncology of Southern Switzerland
What is new in HR+ Breast Cancer? Olivia Pagani Breast Unit and Institute of oncology of Southern Switzerland Outline Early breast cancer Advanced breast cancer Open questions Outline Early breast cancer
More informationWhen is Chemotherapy indicated in Advanced Luminal Breast Cancer?
When is Chemotherapy indicated in Advanced Luminal Breast Cancer? Soo-Chin Lee Head & Senior Consultant Department of Haematology-Oncology Clinical Care National University Cancer Institute, Singapore
More informationNSABP: FB-11. Shannon Puhalla, MD
NSABP: FB-11 Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib with Letrozole as Neoadjuvant Therapy in Post- Menopausal Women with Estrogen Receptor
More informationTRIALs of CDK4/6 inhibitor in women with hormone-receptor-positive metastatic breast cancer
TRIALs of CDK4/6 inhibitor in women with hormone-receptor-positive metastatic breast cancer Marta Bonotto Department of Oncology University Hospital of Udine TRIALs of CDK4/6 inhibitor in women with hormone-receptor-positive
More informationDisease Update: Metastatic Breast Cancer
Disease Update: Metastatic Breast Cancer Aimee Faso, PharmD, BCOP, CPP Oncology Clinical Specialist, GI/Breast UNC Hospitals and Clinics August 2015 Objectives Identify treatment choices of metastatic
More informationCDK4/6 inhibitors in advanced hormone receptor-positive breast cancer
Perspective CDK4/6 inhibitors in advanced hormone receptor-positive breast cancer Romualdo Barroso-Sousa, Sara M. Tolaney Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA Correspondence
More informationTranslational Platform for the Development of Targeted Therapeutics
Translational Platform for the Development of Targeted Therapeutics Ondřej Kalous, MD Associate Project Scientist UCLA Translational Oncology Research Laboratories (TORL) Jonsson Comprehensive Cancer Center
More informationCDK 4/6 Inhibitors: Efficacy and Side Effect Profile
CDK 4/6 Inhibitors: Efficacy and Side Effect Profile Univ.-Prof. Dr. Christian F Singer, MPH Center for Breast Health, Medical University of Vienna Center for Familial Breast- and Ovarian Cancer, MUW Christian
More informationEndocrine Therapy 2017: Is There a Better Single Agent and when Should we Use it?
Endocrine Therapy 2017: Is There a Better Single Agent and when Should we Use it? ET1 ET2 ET3 Targeted agent 1 Targeted agent 2 Hope S. Rugo, MD Director, Breast Oncology and Clinical Trials Education
More informationTerapia adiuvante con inibitori delle Kinasi Cliclina Dipendenti 4/6: quale futuro? Filippo Montemurro
Terapia adiuvante con inibitori delle Kinasi Cliclina Dipendenti 4/6: quale futuro? Filippo Montemurro Unit of Investigative Clinical Oncology Istituto di Candiolo (IRCCS) Disclosures Speaker s Honoraria
More informationAdvances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings. Eve Rodler, MD University of California at Davis October 2016
Advances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings Eve Rodler, MD University of California at Davis October 2016 17th Annual Advances in Oncology September 30-October 1, 2016
More informationUpdates From San Antonio Breast Cancer Symposium 2017
Updates From San Antonio Breast Cancer Symposium 2017 Rob Coleman University of Sheffield Presentation Outline New Insights into adjuvant endocrine treatment Duration of treatment Perioperative therapy
More informationFirst-Line Ribociclib + Letrozole for Postmenopausal Women With HR+, HER2-, Advanced Breast Cancer: First Results From the Phase III MONALEESA-2 Study
First-Line Ribociclib + Letrozole for Postmenopausal Women With HR+, HER2-, Advanced Breast Cancer: First Results From the Phase III MONALEESA-2 Study Abstract LBA1 Hortobagyi GN, Stemmer SM, Burris HA,
More informationNovel Strategies in Systemic Therapies: Overcoming Endocrine Therapy Resistance
Novel Strategies in Systemic Therapies: Overcoming Endocrine Therapy Resistance Richard S. Finn, MD Division of Hematology/ Oncology Director, Translational Oncology Laboratory Geffen School of Medicine
More informationMechanisms of hormone drug resistance
Mechanisms of hormone drug resistance Ljiljana Stamatović Institute for Oncology and Radiology of Serbia Tenth UMOS Conference, Belgrade, 16-17 th May 2015. Hormone receptor-positive breast cancer (HR+
More informationTranscript and References
Richard S. Finn, MD Associate Professor of Medicine Division of Hematology/Oncology Co-director, Signal Transduction and Therapeutics Program Jonsson Comprehensive Cancer Center Geffen School of Medicine
More informationPharmacology Updates in Breast Cancer Chris Vaklavas, M.D.
Pharmacology Updates in Breast Cancer Chris Vaklavas, M.D. Assistant Professor Department of Medicine, Division of Hematology/Oncology University of Alabama at Birmingham NP2540M 1802 6th Avenue South
More informationManejo do câncer de mama RH+ na adjuvância: o que há de novo?
II Simpósio Internacional de Câncer de Mama para o Oncologista Clínico Manejo do câncer de mama RH+ na adjuvância: o que há de novo? INGRID A. MAYER, MD, MSCI Assistant Professor of Medicine Director,
More informationCase #2: Hormonal Therapy for Advanced Premenopausal Breast Cancer
Case #2: Hormonal Therapy for Advanced Premenopausal Breast Cancer Fellow Presenter: Katherine Clifton, MD Faculty Discussant: Debu Tripathy, MD 7 th Annual June 1, 2018 Topics to Be Discussed: Staging
More informationOnline-Only Supplementary Materials
Online-Only Supplementary Materials Online-Only Supplementary Methods: Eligibility Criteria and Study Endpoints and Assessments Supplementary Table 1. Demographic and Baseline Characteristics in Patients
More informationSesiones interhospitalarias de cáncer de mama. Revisión bibliográfica 4º trimestre 2015
Sesiones interhospitalarias de cáncer de mama Revisión bibliográfica 4º trimestre 2015 Selected papers Prospective Validation of a 21-Gene Expression Assay in Breast Cancer TAILORx. NEJM 2015 OS for fulvestrant
More informationPROGNOSTICO DE PACIENTES COM CA DE MAMA METASTATICO HER2+: PODEMOS FAZER MAIS? TDM-1 AND BEYOND!
II Simpósio Internacional de Câncer de Mama para o Oncologista Clínico PROGNOSTICO DE PACIENTES COM CA DE MAMA METASTATICO HER2+: PODEMOS FAZER MAIS? TDM-1 AND BEYOND! INGRID A. MAYER, MD, MSCI Assistant
More informationBreast cancer update. Iryna Kuchuk, MD Oncology department Meir Medical Center
Breast cancer update Iryna Kuchuk, MD Oncology department Meir Medical Center Overview Cancer Death Rates* Among Women, US,1930-2009 Factors Associated with Reduction In Breast Cancer Mortality Early
More informationDieta Brandsma, Department of Neuro-oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
What is hot in breast cancer brain metastases? Dieta Brandsma, Department of Neuro-oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands 8th Annual Brain Metastases Research and Emerging Therapy
More informationPro: Hormone Therapy in HR positive MBC is the preferred option!
Pro: Hormone Therapy in HR positive MBC is the preferred option! Alexandru Eniu, MD, PhD Medical Oncologist Head, Day Hospital Unit Department of Breast Tumors Cancer Institute Ion Chiricuţă Cluj-Napoca,
More informationOpen Clinical Trials: What s Out There Now Paula D. Ryan, MD, PhD
Open Clinical Trials: What s Out There Now Paula D. Ryan, MD, PhD Hanahan and Weinberg, 2000 Acquired Capabilities of Cancer Clinical Trials When should I consider a clinical trial? How do I find the right
More informationManagement of hormone-receptor positive human epidermal receptor 2 negative advanced or metastatic breast cancers
Review Article Page 1 of 10 Management of hormone-receptor positive human epidermal receptor 2 negative advanced or metastatic breast cancers Roger K. C. Ngan Department of Clinical Oncology, Queen Elizabeth
More informationKarcinom dojke. PANEL: Semir Bešlija, Zdenka Gojković, Robert Šeparović, Tajana Silovski
Karcinom dojke PANEL: Semir Bešlija, Zdenka Gojković, Robert Šeparović, Tajana Silovski MBC: HER2 PHEREXA: Study Design Multicenter, randomized, open-label phase III trial Stratified by prior CNS disease,
More informationCancers du Sein Métastatiques
Cancers du Sein Métastatiques Véronique Diéras Journée Laurence Leroyer Rennes 18 mai 2018 Plan ESME Inhibiteurs CDK 4/6 RH+ Inhibiteurs PARP Anticorps drogue-conjugués Perspectives 2018-2019 ESME Time
More informationBreast Cancer: ASCO Poster Review
Breast Cancer: ASCO Poster Review Carmen Criscitiello, MD, PhD Istituto Europeo di Oncologia Milano HER2+ SUBTYPE Research questions in early HER2+ BC De-escalation of toxicity without compromising efficacy
More informationCurrent Optimal Sequence and Duration of Endocrine Treatment
[Symposium 7] Present and Future of Endocrine Therapy 07 Apr, 2018@GBCC Current Optimal Sequence and Duration of Endocrine Treatment Breast Oncology Center The Cancer Institute Hospital of JFCR Shinji
More informationRecent Update in Management of Breast Cancer: Medical Oncology. Jin Hee Ahn, M.D., PhD. 23-April-2015
2015 GBCC & 4 th IBCS 1/37 Recent Update in Management of Breast Cancer: Medical Oncology Jin Hee Ahn, M.D., PhD. 23-April-2015 Department of Oncology, Asan Medical Center, UUCM, Seoul, Korea 2/37 3/37
More informationDEJEUNER-DEBAT Alternatives d administration des chimiothérapies (Session Plénière ) Salle : Salle Camille Blanc
DEJEUNER-DEBAT Alternatives d administration des chimiothérapies (Session Plénière ) Salle : Salle Camille Blanc Revue des essais cliniques en cours et perspectives Dr Cristian Villanueva CHRU Besançon
More informationAggiornamenti tra ricerca e clinica: il carcinoma della mammella
Aggiornamenti tra ricerca e clinica: il carcinoma della mammella Filippo Montemurro Unit of (INCO) Fondazione del Piemonte per l Oncologia Candiolo Cancer Institute (IRCCs) Research Needs in Breast Cancer
More informationPost-ESMO 2012: Tamara Rordorf Klinik für Onkologie UniversitätsSpital Zürich T.Rordorf, SAMO Luzern 1
Post-ESMO 2012: Breast Cancer Tamara Rordorf Klinik für Onkologie UniversitätsSpital Zürich 1 Neoadjuvant treatment (in Her-2 positive disease) neoadjuvant trials abstracts: breast sparing surgery, biomarkers,
More informationState-of-the-Art Update: CDK4/6 Inhibitors in ER+ Metastatic Breast Cancer
State-of-the-Art Update: CDK4/6 Inhibitors in ER+ Metastatic Breast Cancer Neil Vasan, MD, PhD, and Maura N. Dickler, MD Abstract Cell-cycle inhibition is a new standard-of-care therapy in estrogen-receptor
More informationASCO 2018 Breast Cancer Highlights
ASCO 2018 Breast Cancer Highlights Angie DeMichele, MD, MSCE Jill & Alan Miller Endowed Chair in Breast Cancer Excellence Professor of Medicine and Epidemiology Co-Leader, Breast Cancer Program, Abramson
More informationASCO 2017 BREAST CANCER HIGHLIGHTS
Post-ASCO 24 th June 2017, Dolce La Hulpe, Belgium ASCO 2017 BREAST CANCER HIGHLIGHTS Martine J. Piccart-Gebhart, MD, PhD Jules Bordet Institute, Brussels, Belgium Université Libre de Bruxelles Breast
More informationMechanisms of Resistance to. Lisa A. Carey, M.D. University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center
Mechanisms of Resistance to Hormonal Therapy Lisa A. Carey, M.D. University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center Antagonizing Estrogen Dependent Growth Premenopausal
More informationCollaborative Management of Patients With Advanced Estrogen Receptor Positive Breast Cancer
Collaborative Management of Patients With Advanced Estrogen Receptor Positive Breast Cancer Lee Schwartzberg, MD, FACP Heather Greene, FNP, AOCNP West Cancer Center Memphis, Tennessee Learning Objectives
More informationThe lancet oncology 16.1 (2015): 25-35
The lancet oncology 16.1 (2015): 25-35 The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptorpositive,
More informationHighlights of. Metastatic & Advanced Breast Cancer
Highlights of Metastatic & Advanced Breast Cancer 1 Financial Disclosure(s) I currently have or have had the following relevant financial relations to disclose: Speaker s Bureau: Novartis 2 Off Label Use
More informationBest of San Antonio 2008
Best of San Antonio 2008 Ellie Guardino, MD/PhD Assistant Professor Stanford University BIG 1 98: a randomized double blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant
More informationEndocrine treatment might NOT be the preferred option in Hrpos MBC. Dr. Mircea Dediu Sanador Hospital Bucharest Summer School Bucharest 2015
Endocrine treatment might NOT be the preferred option in Hrpos MBC Dr. Mircea Dediu Sanador Hospital Bucharest Summer School Bucharest 2015 Overall survival not improved by the AI treatment Benefit in
More informationA vision for HER2 future
School of Medical Oncology Department of Medical and Biological Sciences - University of Udine Department of Oncology - University Hospital of Udine A vision for HER2 future Current therapeutic algorithm
More informationEndocrine Therapy for Advanced Breast Cancer (ABC) Dr Yoon-Sim YAP Division of Medical Oncology, National Cancer Centre Singapore
Endocrine Therapy for Advanced Breast Cancer (ABC) Dr Yoon-Sim YAP Division of Medical Oncology, National Cancer Centre Singapore Outline Guidelines and Evolving Clinical Treatment Landscape for HR+ HER2-
More informationImmunoconjugates in Both the Adjuvant and Metastatic Setting
Immunoconjugates in Both the Adjuvant and Metastatic Setting Mark Pegram, M.D. Director, Stanford Breast Oncology Program Co-Director, Molecular Therapeutics Program Trastuzumab Treatment of Breast Tumor
More informationUpdate mbc. endokrine Therapie
Update mbc endokrine Therapie HR neg ER pos Endokrine Resistenz Endokrine Therapie 1 st line Postmenopause AI/Tam/Fulvestrant 84% AI+ Fulvestrant 33% AI (Tam) + Everolimus 84% AI + CDK4/6 92% Prämenopause
More informationOptimization of Hormone Treatment: New Alternative Sequences
Optimization of Hormone Treatment: New Alternative Sequences ET1 ET2 ET3 Targeted agent 1 Targeted agent 2 Hope S. Rugo, MD Professor of Medicine Director, Breast Oncology and Clinical Trials Education
More informationVerzenio (abemaciclib) NEW PRODUCT SLIDESHOW
Verzenio (abemaciclib) NEW PRODUCT SLIDESHOW Introduction Brand name: Verzenio Generic name: Abemaciclib Pharmacological class: Kinase inhibitor Strength and Formulation: 50mg, 100mg, 150mg, 200mg; tabs
More informationTreatment of Metastatic Breast Cancer. Prof RCCoombes Imperial College London
Treatment of Metastatic Breast Cancer Prof RCCoombes Imperial College London Metastatic Breast Cancer: General Guidelines Specialized oncology nurses (if possible specialized breast nurses) should be part
More informationIntroduction. Ahmad Radzi 1*, Fabian Wei Luen Lee 2 REVIEW ARTICLE
doi: 10.18282/amor.v4.i1.255 REVIEW ARTICLE Optimizing treatment-sequencing strategies for the management of postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: A
More informationTargeted Agents In Breast Cancer. Wonderful Music With New Instruments
Targeted Agents In Breast Cancer Wonderful Music With New Instruments 1 Trends In Cancer Mortality In Women in US At This Rate We Will Beat Breast Cancer In 2040 Is the cause screening?? Is the cause better
More informationFirst-in-Class CDK4/6 Inhibitor Palbociclib Could Usher in a New Wave of Combination Therapies for HR+, HER2 Breast Cancer
First-in-Class CDK4/6 Inhibitor Palbociclib Could Usher in a New Wave of Combination Therapies for HR+, HER2 Breast Cancer Jack McCain In February 2015, the Food and Drug Administration (FDA) approved
More informationOncology. A CME-certified Supplement to the. Journal of the National Comprehensive Cancer Network. Program Overview/Statement of Need
JNCCN Volume 16 1 Journal of the National Comprehensive Cancer Network A CME-certified to the Journal of the National Comprehensive Cancer Network Program Overview/Statement of Need Recently updated guidelines
More informationSYNOPSIS PROTOCOL TALBOT
SYNOPSIS PROTOCOL TALBOT A) CLINICAL TRIAL IDENTIFICATION SPONSOR - PROTOCOL CODE NUMBER : VERSION: SYNOPSIS V4.0-30/06/2015 TRIAL TITLE : Open-label, randomized, multicenter, phase II study, comparing
More informationMetastatic HR+ Breast Cancer - CDK 4/6 Inhibitors Charting the Path. Sandy Sehdev MD FRCPC
Metastatic HR+ Breast Cancer - CDK 4/6 Inhibitors Charting the Path Sandy Sehdev MD FRCPC Objectives To understand the approach to the treatment of hormone sensitive metastatic breast cancer and the use
More informationHormonal Management of Metastatic Breast Cancer
Hormonal Management of Metastatic Breast Cancer Dr. Khaled Abulkhair, PhD Medical Oncology SCE, Royal College, UK Ass. Professor of Clinical Oncology Mansoura University, Egypt Case For Discussion A 63
More informationBreast cancer treatment
Report from the San Antonio Breast Cancer Symposium Breast cancer treatment Determining the best options for select patient groups Sara Soldera, MD, Resident; Nathaniel Bouganim, MD, FRCPC, Medical Oncologist;
More informationSession Breast Cancer. Alessandra Fabi Il punto di vista dell esperto
Session Breast Cancer Alessandra Fabi Il punto di vista dell esperto Roma 6-7.10.2017 The Importance of Understanding What Disease to Treat Cejalvo et al, Cancer Res 2017 Skyline Chaging at evolution of
More informationEvolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents
Evolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents Kimberly L. Blackwell MD Professor Department of Medicine and Radiation Oncology Duke University Medical Center
More information6/22/2017 TARGETING THE TARGETS IN 2017 TARGETING THE TARGETS IN 2017
TARGETING THE TARGETS IN 2017 Primary Care Focus Symposium July 1, 2017 Grace Wang MD I do not have any relevant financial relationships to disclose at this time TARGETING THE TARGETS IN 2017 What are
More informationEndocrine Therapy in Breast Cancer: State of the Art
Endocrine Therapy in Breast Cancer: State of the Art 12 AUG 2018 Mark Pegram, M.D. Susy Yuan-Huey Hung Professor of Oncology Associate Director for Clinical Research Director, Stanford Breast Oncology
More informationDR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID
DR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID RESUMEN DE ARTICULOS THERESA BOLERO 3 NOAH UP-DATE GEPAR SIXTO RADIOTHERAPY EBCTCG CTCs MISCELANEAS Lancet Oncol 2014;
More informationPredicting outcome in metastatic breast cancer
Predicting outcome in metastatic breast cancer Aleix Prat, MD, PhD Medical Oncology Department Translational Genomics and Targeted Therapeutics in Solid Tumors Monday, 15 th January, Manchester, UK Disclosures
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Everolimus (Afinitor) for Advanced Breast Cancer March 25, 2013
pan-canadian Oncology Drug Review Final Clinical Guidance Report Everolimus (Afinitor) for Advanced Breast Cancer March 25, 2013 DISCLAIMER Not a Substitute for Professional Advice This report is primarily
More informationCohort D Xentuzumab + abemaciclib + fulvestrant (500 mg/month) Key exclusion criteria RP2D-4 NSCLC. Cohort F Xentuzumab + abemaciclib + fulvestrant
A phase Ib trial of xentuzumab and abemaciclib in patients with locally advanced or metastatic solid tumors, including hormone receptor-positive, HER2-negative breast cancer (plus endocrine therapy) Douglas
More informationClinical Spotlight Key Advances in Hormone Receptor Positive Breast Cancer: Updates From the 2018 Oncology Annual Meeting in Chicago
Clinical Spotlight Key Advances in Hormone Receptor Positive Breast Cancer: Updates From the 2018 Oncology Annual Meeting in Chicago Reference Slide Deck Abstract 1000 Abstract 1001 Abstract 1002 Abstract
More informationThe benefit of abemaciclib in prognostic subgroups: An exploratory analysis of combined data from the MONARCH 2 and 3 studies
The benefit of in prognostic subgroups: An exploratory analysis of combined data from the MONARCH 2 and 3 studies Matthew P. Goetz¹, Joyce O Shaughnessy², George W. Sledge Jr.³, Miguel Martin⁴, Yong Lin⁵,
More informationClinical activity of fulvestrant in metastatic breast cancer previously treated with endocrine therapy and/or chemotherapy
ORIGINAL ARTICLE 2018 Mar 16. [Epub ahead of print] Clinical activity of fulvestrant in metastatic breast cancer previously treated with endocrine therapy and/or chemotherapy Mi Hwa Heo, Hee Kyung Kim,
More information10/15/2012. Overcoming Endocrine Therapy Resistance. The Problem in ER+ Tumors is Endocrine Therapy Resistance
Overcoming Endocrine Therapy Resistance Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology Slide Credits: Hope Rugo, MD The Problem in ER+ Tumors is Endocrine Therapy Resistance
More informationTarge:ng HER2 in Metasta:c Breast Cancer in 2014
Targe:ng HER2 in Metasta:c Breast Cancer in 2014 Kimberly L. Blackwell MD Professor Department of Medicine and Radia:on Oncology Duke University Medical Center Director, Breast Cancer Program Duke Cancer
More informationRoohi Ismail-Khan, MD, MS
Roohi Ismail-Khan, MD, MS Associate Member Department of Breast Oncology H. Lee Moffitt Cancer Center Associate Professor University of South Florida Department of Oncological Sciences September 27, 2018
More informationperc considered the clinically meaningful results in PFS, a manageable but not insignificant toxicity profile, no significant detriment in QoL, and a need for treatment options that improve survival and
More informationEnhancing Endocrine Therapy for Hormone Receptor Positive Advanced Breast Cancer
Enhancing Endocrine Therapy for Hormone Receptor Positive Advanced Breast Cancer Sung-Bae Kim, MD, PhD Professor, Dept of Oncology, Asan Medical Center University of Ulsan College of Medicine Seoul, Korea
More informationCDK4 and CDK6 Inhibitor
CDK4 and CDK6 Inhibitor Abemaciclib, LY2835219 Derived from Shapiro GI. 1 Drug Discovery Platform: Cancer Cell Signaling JUNIPER: A Randomized Phase 3 Study of Abemaciclib Plus Best Supportive Care Versus
More informationLA MALATTIA METASTATICA. La malattia HR positiva/her2 negativa: quale terapia di I linea? Come scegliere? Jennifer Foglietta P.O.
LA MALATTIA METASTATICA La malattia HR positiva/her2 negativa: quale terapia di I linea? Come scegliere? Jennifer Foglietta P.O. Narni-Amelia (TR) Outline Re-testing metastatic disease Chemo- vs endocrine-therapy
More informationExpanding Therapeutic Strategies for HER2-Positive Metastatic Breast Cancer
Expanding Therapeutic Strategies for HER2-Positive Metastatic Breast Cancer Sara A. Hurvitz, MD, FACP Associate Professor of Medicine University of California Los Angeles Los Angeles, California Trastuzumab
More informationUpdate on the Management of HER2+ Breast Cancer. Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany
Update on the Management of HER2+ Breast Cancer Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany Outline Treatment strategies for HER2-positive metastatic breast cancer since First
More informationJohns Hopkins Clinical Update Webinar
Johns Hopkins Clinical Update Webinar Ben Ho Park, M.D., Ph.D. Department of Oncology Johns Hopkins University February 2015 This presentation is the intellectual property of the author/presenter. Contact
More informationSystemic therapy: HER-2 update. Hans Wildiers Multidisciplinair Borst Centrum/Algemene medische oncologie UZ Leuven
Systemic therapy: HER-2 update Hans Wildiers Multidisciplinair Borst Centrum/Algemene medische oncologie UZ Leuven New drugs Strategic issues Specific anti-her2 drugs Lapa$nib /Nera$nib Baselga & Swain,
More informationHorizon Scanning in Oncology
Horizon Scanning in Oncology Abemaciclib (Verzenio ) in combination with a nonsteroidal aromatase inhibitor (NSAI) as initial therapy for advanced breast cancer (ABC) DSD: Horizon Scanning in Oncology
More informationXII Michelangelo Foundation Seminar
XII Michelangelo Foundation Seminar The opportunity of the neoadjuvant approach L. Gianni, Milan, I XII Michelangelo Foundation Seminar Milano, October 12, 2012 The opportunity of the neoadjuvant approach
More informationMEDICAL ONCOLOGY NEWS IN BREAST CANCER 2014
MEDICAL ONCOLOGY NEWS IN BREAST CANCER 2014 Dr Thomas Yau Clinical Assistant Professor MBBS(HK), MRCP (UK), FHKCP (Med Onc), FHKAM( Medicine), FRCP(London) Queen Mary Hospital The University of Hong Kong
More informationBiomarkers for HER2-directed Therapies : Past Failures and Future Perspectives
Biomarkers for HER2-directed Therapies : Past Failures and Future Perspectives Ian Krop Dana-Farber Cancer Institute Harvard Medical School Inchon 2018 Adjuvant Trastuzumab Improves Outcomes in HER2+ Breast
More informationSystemic Management of Breast Cancer
Systemic Management of Breast Cancer Why Who When What How long Etc. Vernon Harvey Rotorua, June 2014 Systemic Management of Breast Cancer Metastatic Disease Adjuvant Therapy Aims of therapy Quality of
More informationAdvanced HER2+ Breast Cancer: New Options and How to Deploy Them. José Baselga MD, PhD
Advanced HER2 Breast Cancer: New Options and How to Deploy Them José Baselga MD, PhD HER2 signaling results in a multitude of cellular effects, including increased cellular proliferation HER2 HER3 RAS
More information14,30 18,20. II Sessione. Moderatori: Giovanni Apolone, Roberto Labianca
14,30 18,20 II Sessione Moderatori: Giovanni Apolone, Roberto Labianca 14,30 14,50 Ca mammario: attualità e prospettive di ricerca Luca Livraghi Carcinoma mammario: attualità e prospettive di ricerca LUCA
More informationORMONOTERAPIA ADIUVANTE: QUALE LA DURATA OTTIMALE? MARIANTONIETTA COLOZZA
ORMONOTERAPIA ADIUVANTE: QUALE LA DURATA OTTIMALE? MARIANTONIETTA COLOZZA THE NATURAL HISTORY OF HORMONE RECEPTOR- POSITIVE BREAST CANCER IS VERY LONG Recurrence hazard rate 0.3 0.2 0.1 0 ER+ (n=2,257)
More informationPage. Objectives: Hormone Therapy Resistance: Challenges and Opportunities. Research Support From Merck
Hormone Therapy Resistance: Challenges and Opportunities Pamela. N. Munster, MD University of California, San Francisco Financial Disclosures Research Support From Merck Objectives: Understanding the current
More informationESMO SUMMIT MIDDLE EAST 2018
ESMO SUMMIT MIDDLE EAST 2018 Breast Clinical Cases Presentation Hampig Raphael Kourie, MD, MSc, MBioethics Faculty of Medicine, Saint Joseph University of Beirut, Lebanon 6-7 April 2018, Dubai, UAE CONFLICT
More information